NCCN Invasive Breast Cancer Clinical Practice Guidelines in Oncology

2007 ◽  
Vol 5 (3) ◽  
pp. 246 ◽  
Author(s):  
_ _
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Invasive Breast Cancer ◽  
Breast Cancer Mortality ◽  
The United States ◽  
Cancer Society ◽  
The Past ◽  
Recent Version ◽  
Common Malignancy

The American Cancer Society estimates that 214,640 new cases of breast cancer will be diagnosed and 41,430 will die of the disease in the United States in 2006. Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The incidence of breast cancer has steadily increased in the United States over the past few decades, but breast cancer mortality appears to be declining, suggesting a benefit from early detection and more effective treatment. These guidelines discuss diagnosis, treatment, and follow up for invasive breast cancer. For the most recent version of the guidelines, please visit NCCN.org

Breast Cancer Clinical Practice Guidelines in Oncology

2005 ◽  
Vol 3 (3) ◽  
pp. 238 ◽  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Lung Cancer ◽  
Breast Cancer Mortality ◽  
The United States ◽  
Cancer Death ◽  
Cancer Society ◽  
The Past ◽  
Recent Version ◽  
Common Malignancy

The American Cancer Society estimates that approximately 217,440 new cases of breast cancer will have been diagnosed in the United States in the year 2004 and approximately 40,580 patients will die of this disease. Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The incidence of breast cancer has increased steadily in the United States over the past few decades, but breast cancer mortality appears to be declining. This suggests a benefit from early detection and more effective treatment. For the most recent version of the guidelines, please visit NCCN.org

Breast Cancer Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (2) ◽  
pp. 148 ◽  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Invasive Breast Cancer ◽  
The United States ◽  
Cancer Society ◽  
Nccn Guidelines ◽  
Recent Version

The American Cancer Society estimates that approximately 205,000 new cases of breast cancer were diagnosed in the United States in the year 2002, and approximately 40,000 patients will die of this disease. The NCCN guidelines discuss the complex and varied therapeutic options for patients with noninvasive or invasive breast cancer. For the most recent version of the guidelines, please visit NCCN.org

Mammography Surveillance and Mortality in Older Breast Cancer Survivors

2007 ◽  
Vol 25 (21) ◽  
pp. 3001-3006 ◽  
Author(s):  
Timothy L. Lash ◽  
Matthew P. Fox ◽  
Diana S.M. Buist ◽  
Feifei Wei ◽  
Terry S. Field ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Cancer Mortality ◽  
Breast Cancer Survivors ◽  
Care Delivery ◽  
Breast Cancer Mortality ◽  
The United States ◽  
Stage I ◽  
Early Stage Disease

Purpose There are more than 2,000,000 breast cancer survivors in the United States today. While surveillance for asymptomatic recurrence and second primary is included in consensus recommendations, the effectiveness of this surveillance has not been well characterized. Our purpose is to estimate the effectiveness of surveillance mammography in a cohort of breast cancer survivors with complete ascertainment of surveillance mammograms and negligible losses to follow-up. Patients and Methods We enrolled 1,846 stage I and II breast cancer patients who were at least 65 years old at six integrated health care delivery systems. We used medical record review and existing databases to ascertain patient, tumor, and therapy characteristics, as well as receipt of surveillance mammograms. We linked personal identifiers to the National Death Index to ascertain date and cause of death. We matched four controls to each breast cancer decedent to estimate the association between receipt of surveillance mammogram and breast cancer mortality. Results One hundred seventy-eight women died of breast cancer during 5 years of follow-up. Each additional surveillance mammogram was associated with a 0.69-fold decrease in the odds of breast cancer mortality (95% CI, 0.52 to 0.92). The protective association was strongest among women with stage I disease, those who received mastectomy, and those in the oldest age group. Conclusion Given existing recommendations for post-therapy surveillance, trials to compare surveillance with no surveillance are unlikely. This large observational study provides support for the recommendations, suggesting that receipt of surveillance mammograms reduces the rate of breast cancer mortality in older patients diagnosed with early-stage disease.

scholarly journals The Status of Chemotherapy in Metastatic Breast Cancer: Insights for the Advanced Practitioner

2021 ◽  
Vol 12 (2) ◽  
Author(s):  
Kirollos Hanna, PharmD, BCPS, BCOP ◽  
Kelley Mayden, MSN, FNP, AOCNP
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Metastatic Breast Cancer ◽  
Death Rate ◽  
Metastatic Breast ◽  
The United States ◽  
Cancer Society ◽  
Common Cause ◽  
Advanced Practitioner ◽  
The Status

Breast cancer is the most frequently diagnosed cancer in the United States and ranks second as the most common cause of cancer-related death among women (Siegel et al., 2020). According to American Cancer Society (ACS) estimates, approximately 276,480 new cases of breast cancer would have been diagnosed in 2020, and greater than 42,000 deaths would be attributed to breast cancer (ACS, 2020). Although only 7% of all cancer-related deaths are from breast cancer every year, it is the leading cause of death among women between the ages of 40 and 49 years (Siegel et al., 2020). The death rate associated with breast cancer, however, has decreased by 1.3% annually from 2013 to 2017.

scholarly journals Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient

2016 ◽  
Vol 160 (3) ◽  
pp. 573-573
Author(s):  
Thomas M. Churilla ◽  
Brian L. Egleston ◽  
Colin T. Murphy ◽  
Elin R. Sigurdson ◽  
Shelly B. Hayes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Invasive Breast Cancer ◽  
Multidisciplinary Care ◽  
The United States ◽  
Medicare Patient

Breast Cancer in Women with Cystic Disease of the Breast

1965 ◽  
Vol 51 (4) ◽  
pp. 227-236
Author(s):  
Umberto Veronesi ◽  
Giorgio Pizzocaro ◽  
Aldo Vittorio Bono
Keyword(s):  
Breast Cancer ◽  
United States ◽  
At Risk ◽  
National Cancer Institute ◽  
Metropolitan Areas ◽  
The United States ◽  
Contralateral Breast ◽  
Cystic Disease

From 1937 to 1960, 1051 women with cystic disease of the breast were hospitalized at the National Cancer Institute of Milan; 1008 of them were followed for a period ranging from 1 to 26 years, with an average of 8.5 years. All cases were histologically proved. Twenty-one of the patients developed a cancer of the breast; 16 in the breast with the cystic disease, 5 in the contralateral breast. In 667 cases the disease was histologically classified as «simple cystic disease »; 12 of these cases had a breast cancer. In 384 cases the disease was classififed as «hyperplastic cystic disease»; 9 of these developed a cancer of the breast. The follow-up of the 1008 cases provided 8539 person-years at risk; the number of the expected breast cases was calculated on the basis of the Dorn and Cutler data on morbidity of cancer in 10 metropolitan areas of the United States. The number of expected breast cancer was 12.2; the number of observed cases was 21, the ratio between observed and expected cases being 1.71.

Micropallet Technology for Investigating Tumor Cellular Profiles and Analysis of Rare Cell Subsets

2008 ◽  
Author(s):  
Nicholas M. Gunn ◽  
Mark Bachman ◽  
Edward L. Nelson ◽  
G.-P. Li
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Patients ◽  
Invasive Breast Cancer ◽  
Breast Tumor ◽  
The United States ◽  
Therapeutic Strategies ◽  
Cellular Heterogeneity ◽  
Breast Cancer Patients ◽  
Critical Limits

Rationally designed, individualized therapeutic strategies have long been a desired objective for breast cancer patients and clinicians as an estimated 178,480 new cases of invasive breast cancer will be diagnosed among women in the United States this year and over 40,000 women are expected to die from the disease. [1] The increasing appreciation of breast tumor cellular heterogeneity raises fundamental questions as to the relative contributions of cellular subsets to the biologic behavior of an individual patient’s tumor. [2] As such, it has become increasingly clear that in many cases, an individualized strategy for the treatment of breast cancer would be of great benefit, and that the ability to isolate relevant cellular subsets from the main tumor population is one of the critical limits to accomplishing this goal.

scholarly journals Role of Hormones in Cancer Prevention

2014 ◽  
pp. 34-40 ◽  
Author(s):  
Victor G. Vogel
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitor ◽  
Postmenopausal Women ◽  
Invasive Breast Cancer ◽  
White Women ◽  
Risk Index ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Increased Risk

Risk for breast cancer can be easily and rapidly assessed using validated, quantitative models. Multiple randomized studies show that the selective estrogen response modifiers (SERMs) tamoxifen and raloxifene can safely reduce the risk of invasive breast cancer in both pre- and postmenopausal women. Treatment resulted in a 38% reduction in breast cancer incidence, and 42 women would need to be treated to prevent one breast cancer event in the first 10 years of follow-up. Reduction was larger in the first 5 years of follow-up than in years 5 to 10, but no studies treated patients for longer than 5 years. Thromboembolic events were significantly increased with all SERMs, whereas vertebral fractures were reduced. Tamoxifen provides net benefit to all premenopausal women who are at increased risk, whereas raloxifene reduces risk nearly as much in postmenopausal women and offers increased safety. Both tamoxifen and raloxifene reduce the incidence of in situ cancers. Lasofoxifene reduced the risk of breast cancer by 79% in postmenopausal women with osteoporosis. The MAP3 trial showed a 65% reduction in the annual incidence of invasive breast cancer in postmenopausal women who were at moderately increased risk for breast cancer who took the aromatase inhibitor exemestane. The IBIS-II trial showed a 53% reduction in the risk of invasive breast cancer in postmenopausal women aged 40 to 70 who took the aromatase inhibitor anastrozole. Of the 50 million white women in the United States aged 35 to 79, 2.4 million would have a positive benefit/risk index for chemoprevention.

Sign in / Sign up

Export Citation Format

Share Document